Related Experiment Video
Updated: Aug 18, 2026
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
Small molecules with EGFR-TK inhibitor activity
1Medical Oncology Department, ICMHO & Unitat de Patologia Mamaria & IDIBAPS. Hospital Clinic, Barcelona, Spain. albanell@clinic.ub.es
Abstract:
Specific and reversible EGFR tyrosine kinase inhibitors (TKI) such as gefitinib and erlotinib are clinically active in advanced or metastatic NSCLC and both are approved in various countries for the treatment of patients that failed prior chemotherapy. Erlotinib has also prolonged survival in pancreatic cancer patients when added to gemcitabine and regulatory approval in this disease is being sought. Additional promising activity has been seen in other tumor types, such as ovarian cancer or head and neck malignancies, and phase III trials in these malignancies are ongoing or planned. Despite these successes, these agents have exhibited anecdotal or modest activity when used as single agents in unselected patients with various other tumor types. We have learned that the clinical development of these agents is far from simple and we need to better understand biological and clinical criteria for patient selection and how to best use the different available agents. The recent discovery of EGFR mutations and the potential identification of other markers that might predict patient response could help to optimize the use of these agents in the future. Irreversible EGFR inhibitors, dual EGF/HER2 and pan-ErbB receptor inhibitors may have greater antitumor activity although the tolerance of these compounds compared to specific EGFR TKIs needs further characterization. HER2 specific TKIs are also in development. Lapatinib, a dual EGFR/HER2 TK inhibitors, is particularly promising in breast cancer. Newer agents, such as BMS-599626, have recently entered into the clinic. In addition to the use of these agents as single agents, many clinical studies are addressing the role of combining them with hormonal agents, biological agents or chemotherapy.
Insights
Specific EGFR tyrosine kinase inhibitors (TKIs) show promise in treating cancers like NSCLC and pancreatic cancer. Optimizing patient selection through biomarkers like EGFR mutations is key for future TKI development and combination therapies.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Specific and reversible EGFR tyrosine kinase inhibitors (TKIs) demonstrate clinical activity in advanced or metastatic non-small cell lung cancer (NSCLC) and pancreatic cancer.
- Erlotinib is approved for NSCLC post-chemotherapy and shows survival benefits in pancreatic cancer when combined with gemcitabine.
- Activity is also observed in ovarian cancer and head and neck malignancies, with ongoing or planned Phase III trials.
Purpose of the Study:
- To explore the clinical development of EGFR TKIs, emphasizing the need for better patient selection criteria.
- To investigate the potential of newer irreversible EGFR inhibitors, dual EGF/HER2 inhibitors, and pan-ErbB receptor inhibitors.
- To assess the role of combining TKIs with other therapeutic agents like hormonal agents, biological agents, or chemotherapy.
Main Methods:
- Review of clinical activity and ongoing trials of specific and reversible EGFR TKIs.
- Examination of emerging irreversible EGFR inhibitors, dual inhibitors, and pan-ErbB receptor inhibitors.
- Analysis of combination therapy studies involving TKIs with other treatment modalities.
Main Results:
- While effective in selected populations (e.g., EGFR-mutated NSCLC), TKIs show modest activity in unselected patients.
- Newer generation inhibitors (irreversible, dual, pan-ErbB) may offer greater antitumor activity, requiring further tolerance characterization.
- Lapatinib (dual EGFR/HER2 TKI) shows promise in breast cancer; novel agents like BMS-599626 are entering clinical trials.
Conclusions:
- Understanding biological and clinical criteria for patient selection is crucial for optimizing TKI therapy.
- EGFR mutations and other potential biomarkers can guide patient selection for improved outcomes.
- Future research directions include evaluating novel inhibitors and combination strategies to enhance efficacy and overcome resistance.
Related Concept Videos
02:38Mitogens and the Cell Cycle
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include: